WNT5A and stage 5 chronic kidney disease: In addition, in a severe ARPKD sub-group where patients reached end stage renal disease at an age of 5 years or younger, there was a 2.7-fold increase in WNT5A mRNA expression (Fig. 7B, n = 6, p < 0.05).